Oxford, UK: 25 July 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that the independent Data Safety Monitoring Board (DSMB) for the Phase III TRIST study of TroVax in renal cancer has completed its first scheduled interim analysis. The DSMB concluded that the trial should continue as planned without modifcation. The DSMB reviewed safety and anticancer immune responses from the first 50 patients enrolled. TroVax is Oxford BioMedica’s novel cancer immunotherapy product, which is being developed in collaboration with sanofi-aventis.
